Septic shock, multiple organ failure, and acute respiratory distress syndrome

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 3, 2003, Pages 199-209

  Sharma, Sat ^a,b   Kumar, Anand ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALBUMIN I 125; ANTIBIOTIC AGENT; CELL ADHESION MOLECULE; CORTICOSTEROID; CYTOKINE; DOPAMINE; DROTRECOGIN; ENDOTOXIN ANTIBODY; FLUDROCORTISONE; GLUCOSE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; IMMUNOMODULATING AGENT; INOTROPIC AGENT; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; LUNG SURFACTANT; NITRIC OXIDE; NORADRENALIN; PHENYLEPHRINE; PLACEBO; TERLIPRESSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ANTIBODY; VASOPRESSIN;

ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CRITICAL ILLNESS; DOUBLE BLIND PROCEDURE; FLUID THERAPY; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; IMMUNE SYSTEM; INSULIN TREATMENT; INTENSIVE CARE UNIT; KIDNEY FAILURE; LIQUID VENTILATION; MAJOR CLINICAL STUDY; MALNUTRITION; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NUTRITIONAL SUPPORT; PHASE 2 CLINICAL TRIAL; POSITIVE END EXPIRATORY PRESSURE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS SYNDROME; RESUSCITATION; REVIEW; SEPTIC SHOCK; SEPTICEMIA;

ANTI-BACTERIAL AGENTS; CANADA; CAUSE OF DEATH; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; FLUID THERAPY; HUMANS; INCIDENCE; MALE; MULTIPLE ORGAN FAILURE; PROGNOSIS; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SURVIVAL ANALYSIS;

EID: 0037403909     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200305000-00008     Document Type: Review

References (112)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al.: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001, 29:1303-1310. An epidemiologic study conducted in the United States to determine incidence, associated costs, and outcome of severe sepsis.
2. Increase in National Hospital Discharge Survey rates for septicemia-United States, 1979-1987. MMWR Morb Mortal Wkly Rep 1990, 39:31-34.
3. Bone RC, Balk RA, Cerra FB, et al: American College of Chest Physicians/Society of Critical Care Medicine Concensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992, 101:1644-1655.
4. Rangel-Frausto M, Pittet D, Costigan M, et al.: The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 1995, 273:117-123.
5. Youkeles LH, Rosen MJ: The epidemiology of sepsis in the immunocompromised host. In Sepsis and Multiple Organ Failure. Edited by Fein AM, Abraham EM, Balk RA, et al. Baltimore: Williams & Wilkins;1997:35-42.
6. Aube H, Milan C, Blettery B: Risk factors for septic shock in the early management of bacteremia. Am J Med 1992, 93:283-288.
7. Christman JW, Wheeler AP, Bernard GR: Cytokines and Sepsis: what are the therapeutic implications? J Intensive Care 1991, 6:172-182.
8. Schindler R, Mancilla J, Endres S, et al.: Correlations and interactions in the production of interleukin-6 (IL-6), IL-1 and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990, 75:40-47.
9. Vervloet MG, Thijs LG, Hack CE: Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998, 24:33-44.
10. Bajzar L, Neshelm ME, Tracy PB: The profibrinolytic effect of activated protein C in clots formed from plasma as TAF1-dependent. Blood 1996, 88:2093-2100.
11. Angus DC, Birmingham MC, Balk RA, et al.: E5 murine monoclonal antiendotoxin antibody in gram negative sepsis: a randomized controlled trial. JAMA 2000, 283:1723-1729.
12. Fisher CJ, Jr, Agosti JM, Opal SM, et al.: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Eng J Med 1996, 334:1697-1702.
13. Fisher CJ, Slotman GJ, Opal SM, et al.: The IL-1ra Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994, 22:12-21.
14. Kollef MH, Sherman G, Ward S, et al.: Inadequate antimicrobial treatment of infections. A risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
15. Beal AL, Cerra FB: Multiple organ failure syndrome in the 1990s: systemic inflammatory response and organ dysfunction. JAMA 1994, 271:226-233.
16. Cortez A, Zito J, Lucas CE, et al.: Mechanism of inappropriate polyuria in septic patients. Arch Surg 1977, 112:471-476.
17. Elliott DC: An evaluation of the end points of resuscitation. J Am Coll Surg 1998, 187:536-547.
18. Rivers E, Nguyen B, Havstad S, et al.: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377. This study evaluated the efficacy of early goal directed hemodynamic optimization of patients with septic shock prior to intensive care unit admission.
19. Boldt J: Volume therapy in the intensive care patient-we are still confused, but.... Intensive Care Med 2000, 26:1181-1192.
20. Webb AR, Tighe D, Moss RF, et al.: Advantages of a narrow-range, medium molecular weight hydroxyethyl starch for volume maintenance in a porcine model of fecal peritonitis. Crit Care Med 1991, 19:409-416.
21. Morisaki H, Bloos F, Keys J, et al.: Compared with crystalloid, colloid therapy slows progression of extrapulmonary tissue injury in septic sheep. J Appl Physiol 1994, 77:1507-1518.
22. Lum H, Siflinger-Birnboim A, Blumenstock F, et al.: Serum albumin decreases transendothelial permeability to macromolecules. Microvasc Res 1991, 42:91-102.
23. Marx G, Cobas Meyer M, Schuerholz T, et al.: Hydroxyethyl starch and modified fluid gelatin maintain plasma volume in a porcine model of septic shock with capillary leakage. Intensive Care Medicine 2002, 28:629-635.
24. Margarson MP, Soni NC: Effects of albumin supplementation on microvascular permeability in septic patients. J Appl Physiol 2002, 92:2139-2145. This study addresses whether albumin infusion in critically ill septic patients improves microvascular permeability.
25. Schierhout G, Roberts I: Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomized trials. BMJ 1998, 316:961-964.
26. Choi PT, Yip G, Quinonez LG, et al.: Crystalloids vs colloids in fluid resuscitation: a systematic review. Crit Care Med 1999, 27:200-210.
27. Martin C, Papazian L, Perrin G, et al.: Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993, 103:1826-1831.
28. Desjars P, Pinaud M, Potel G, et al.: A reappraisal of norepinephrine therapy in human septic shock. Crit Care Med 1987, 15:134-137.
29. Hannemann L, Reinhart K, Grenzer O, et al.: Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. Crit Care Med 1995, 23:1962-1970.
30. Gregory JS, Bonfiglio MF, Dasta JF, et al.: Experience with phenylepherine as a component of the pharmacologic support of septic shock. Crit Care Med 1991, 19:1395-1400.
31. Kumar A, Parrillo JE: Shock: Classification, Pathophysiology, And Approach To Management in Critical Care Medicine: Principles of Diagnosis and Management, edn 2. Edited by Parillo JE, Dellinger RP. St. Louis: Mosby Publications;2001:371-420.
32. Kumar A, Haery C, Parrillo JE: Myocardial dysfunction in septic shock. Crit Care Clin 2000, 16:251-287.
33. Levy B, Bollaert PE, Charpentier C, et al.: Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997, 23:282-287.
34. Silva E, DeBacker D, Créteur J, et al.: Effects of vasoactive drugs on gastric intramucosal pH. Crit Care Med 1998, 26:1749-1758.
35. Duranteau J, Sitbon P, Teboul JL, et al.: Effects of epinephrine, noepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock. Crit Care Med 1999, 27:893-900.
36. Seguin P, Bellissant E, Le Tulzo Y, et al.: Effects of epinephrine compared with the combination of dobutamine and norepinephrine on gastric perfusion in septic shock. Clinical Pharmacology & Therapeutics 2002, 71:381-388. Prospective study evaluated effect of epinephrine compared with a combination of dobutamine and norepinephrine on gastric mucosal flow in septic shock.
37. Lebuffe G, Levy B, Neviere R, et al.: Dobutamine and gastric-to-arterial carbon dioxide gap in severe sepsis without shock. Intensive Care Med 2002, 28:265-271. This study examines the effect of early dobutamine infusion on gastrointestinal perfusion in patients with severe sepsis.
38. Landry DW, Levin HR, Gallant EM, et al.: Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997, 25:1279-1282.
39. Landry DW, Levin HR, Gallant EM, et al.: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997, 95:1122-1125.
40. Holmes CL, Patel BM, Russell JA, et al.: Physiology of vasopressin relevant to management of septic shock. Chest 2001, 120:989-1002.
41. Tsuneyoshi I, Yamada H, Kakihana Y, et al.: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001, 29:487-493.
42. Patel BM, Chittock DR, Russell JA, et al.: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002, 96:576-582. The goal of this study was to determine whether vasopressin infusion has a vasopressor sparing effect in severe septic shock.
43. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. Lancet 2002, 359:1209-1210.
44. Kellum JA, M Decker J: Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001, 29:1526-1531.
45. Marik PE: Low dose dopamine: a systematic review. Intensive Care Med 2002, 28:877-883.
46. Belllomo R, Chapman M, Hickling K, et al.: Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000, 356:2139-2143.
47. Wolfe RR, Herndon DN, Jahoor F, et al.: Effect of severe burn injury on substrate cycling by glucose and fatty acids. N Engl J Med 1987, 317:403-408.
48. McCowen KC, Malhotra A, Bistrian BR: Stress-induced hyperglycemia. Crit Care Clin 2001, 17:107-124.
49. Van Den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345:1359-1367. This randomized controlled trial was conducted to determine whether normalization of blood glucose levels with intensive insulin therapy reduces mortality and morbidity among critically ill patients.
50. Rothwell PM, Udwadia ZF, Lawler PG: Cortisol response to corticotropin and survival in septic shock. Lancet 1991, 337:582-583.
51. Annane D, Sébille V, Troché G, et al.: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000, 283:1038-1045.
52. Bone RC, Fisher CJ, Clemmer TP, et al.: A controlled clinical trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Eng J Med 1987, 317:654-658.
53. Lamberts SW, Bruining HA, de Jong FH: Corticosteroid therapy in severe illness. N Engl J Med 1997, 337:1285-1292.
54. Annane D, Bellissant E, Sébille V, et al.: Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998, 46:589-597.
55. Bollaert PE, Charpentier C, Levy B, et al.: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998, 26:645-650.
56. Briegel J, Forst H, Haller M, et al.: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999, 27:723-732.
57. Annane D, Sebille V, Charpentier C, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862-871. Replacement therapy with corticosteroids has been proposed, as septic shock may be associated with relative adrenal insufficiency. This randomized controlled trial demonstrated improved survival with adrenal replacement therapy.
58. Esmon CT, Taylor FB Jr, Snow TR: Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991, 66:160-165.
59. Yan SB, Grinnell BW: Recombinant human protein C, protein S, and thrombomodulin as antithrombotics. Perspect Drug Discovery Des 1993, 1:503-520.
60. Esmon CT: The protein C anticoagulant pathway. Arterioscler Thromb 1992, 12:135-145.
61. Fourrier F, Chopin C, Goudemand J, et al.: Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992, 101:816-823.
62. Hartman DL, Bernard GR, Helterbrand JD, et al.: Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis [abstract]. Intensive Care Med 1998, 24(suppl 1):S77.
63. Bernard GR, Vincent J-L, Laterre P-F, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Eng J Med 2001, 344:699-709. First randomized controlled trial of drotrecogin alfa activated demonstrated that mediator targeted therapy is beneficial in severe sepsis and septic shock.
64. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996, 275:1489-1494.
65. Ronco C, Bellomo R, Homel P, et al.: Effect of different doses in continuous veno-venous hemofiltration on outcomes of acute renal failure: a prospective randomized trial. Lancet 2000, 356:26-30.
66. Schiffe H, Lang SM, Fischer R: Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002, 346:305-310. Whether intensive hemodialysis improves survival in critically ill patients is examined in this prospective one center study.
67. Pinsky MR, Vincent JL, Deviere J, et al.: Serum cytokine levels in septic shock: relation to multiple-system organ failure and mortality. Chest 1993, 103:565-575.
68. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996, 24:1125-1127.
69. John S, Griesbach D, Baumgartel M, et al.: Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial. Nephrol Dial Transplant 2001, 16:320-327.
70. Cole L, Bellomo R, Hart G, et al.: A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002, 30:100-106.
71. Reeves JH, Butt WW, Shann F, et al: Continuous plasmafiltration in sepsis syndrome. Crit Care Med 1999, 27:2069-2104.
72. Cole L, Bellomo R, Hart G, et al.: A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002, 30:100-106. The effect of early and continuous venovenous hemofiltration on cytokine levels and organ dysfunction is studied.
73. Ronco C, Brendolan A, Lonnemann G, et al.: A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002, 30:1250-1255.
74. Heyland DK, Cook DJ, Guyatt GH: Enteral nutrition in the critically ill patient: a critical review of the evidence. Intensive Care Med 1993, 19:435-442.
75. Heyland DK: Nutritional support in the critically ill patient. A critical review of the evidence. Crit Care Clin 1998, 14:423-440.
76. Heyland DK, MacDonald S, Keefe L, Drover JW: Total parenteral nutrition in the critically ill patient: a meta-analysis. JAMA 1998, 280:2013-2019.
77. Nakad A, Piessevaux H, Mater JC, et al.: Is early enteral nutrition in acute pancreatitis dangerous? About 20 patients fed by an endoscopically placed nasogastrojejunal tube. Pancreas 1998, 17:187-193.
78. Isenmann R, Buchler MW: Infection and acute pancreatitis. Br J Surg 1994, 81:1707-1708.
79. Olah A, Belagyi T, Issekutz A, et al.: Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002, 89:1103-1107.
80. Vincent JL, Bihari DJ, Suter PM, et al.: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevatence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995, 274:639-644.
81. Lacey JM, Wilmore DW: Is glutamine a conditionally essential amino acid? Nutr Rev 1990, 48:297-309.
82. Griffiths RD: Evidence for glutamine use in the critically ill. Proc Nutr Soc 2001, 60:403-410.
83. Griffiths RD, Jones C, Palmer TEA: Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition. Nutrition 1997, 13:295-302.
84. Griffiths RD, Allen KD, Andrews FJ, et al.: Infection, multiple organ failure, and survival in the intensive care unit: influence of glutamine-supplemented parenteral nutrition on acquired infection. Nutrition 2002, 18:546-552. Parenteral nutrition containing glutamine may not reduce incidence of intensive-care-acquired infections, but may reduce infection associated deaths.
85. Ashbaugh DG, Bigelow DB, Petty T, et al.: Acute respiratory distress syndrome in adults. Lancet 1967, 2:319-323.
86. Sloane PJ, Gee MH, Gottlieb JE, et al.: A multicenter registry of patients with acute respiratory distress syndrome. Am Rev Respir Dis 1992, 146:419-426.
87. Fein AM, Lippman M, Holtzman H, et al.: The risk factors, incidence and prognosis of ARDS following Septicemia. Chest 1983, 83:40-42.
88. Hyers TM: Prediction of survival and mortality in patients with adult respiratory distress syndrome. New Horizons 1993, 1:466-470.
89. Luce JM: Acute lung injury and the acute respiratory distress syndrome. Crit Care Med 1998, 26:369-376.
90. Amato MB, Barbas CS, Medeiros DM, et al.: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998, 338:347-354.
91. Slutsky AS, Raniere VM.: Mechanical ventilation: lesson from the ARDSNet trial. Respir Res 2000, 1:73-77.
92. Dreyfuss D, Basset G, Soler P, et al.: Intermittent positive-end expiratory pressure hyperventilation with high inflation pressures produces pulmonary microvascular injury in rats. Am Rev Respir Dis 1985, 132:880-884.
93. Tremblay L, Valenza F, Ribeiro SP, et al.: Injurious ventilatory strategies increases cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 1997, 99:944-952.
94. Ranieri VM, Suter PM, Tortorella C, et al.: Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 1999, 282:54-61.
95. The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Eng J Med 2000, 342:1301-1308.
96. De Durante G, Del Turco M, Rustichini L, et al.: ARDSNet lower tidal volume ventilatory strategy may generate intrinsic positive end-expiratory pressure in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2002, 165:1271-1274. Is it the lower tidal volumes or the higher total PEEP that is protective in ARDS, this hypothesis is tested in this investigation.
97. Gattinoni L, Pelosi P, Vitale G, et al.: Body position changes redistribute lung computed-tomographic density in patients with acute respiratory failure. Anesthesiology 1991, 74:15-23.
98. Lamm WJ, Graham MM, Albert RK: Mechanism by which the prone position improves oxygenation in acute lung injury. Am J Respir Crit Care Med 1994, 150:184-193.
99. Pappert D, Rossaint R, Slama K, et al.: Influence of positioning on ventilation-perfusion relationships in severe adult respiratory distress syndrome. Chest 1994, 106:1511-1516.
100. Pelosi P, Tubiolo D, Mascheroni D, et al.: Effects of the prone position on respiratory mechanics and gas exchange during acute lung injury. Am J Respir Crit Care Med 1998, 157:387-393.
101. Lee DL, Chiang HT, Lin SL, et al.: Prone-position ventilation induces sustained improvement in oxygenation in patients with acute respiratory distress syndrome who have a large shunt. Crit Care Med 2002, 30:1446-1452. The patients who have large shunts and a more compliant chest wall demonstrate sustained improvement in oxygenation following prone position ventilation.
102. Douglas W, Rehder K, Beynen F, et al.: Improved oxygenation in patients with acute respiratory failure: The prone position. Am Rev Respir Dis 1977, 115:559-566.
103. Pappazian L, Paladini M-H, Bregeon F, et al.: Can the tomographic aspect characteristics of patients presenting with acute respiratory distress syndrome predict improvement in oxygenation-related response to the prone position? Anesthiology 2002, 97:599-604. Why some patients with ARDS improve oxygenation in prone position whereas others do not? Can response to prone position ventilation be predicted?
104. Hering R, Wrigge H, Vorwerk R, et al.: Effects of prone positioning on intraabdominal pressure, cardiovascular and renal function in patients with acute lung injury. Anesth Analg 2001, 92:1226-1231.
105. Hering R, Vorwerk R, Wrigge H, et al.: Prone positioning, systemic hemodynamics, hepatic indocyanine green kinetics, and gastric intramucosal energy balance in patients with acute lung injury. Intensive Care Med 2002, 28:53-58.
106. Arnold JH, Hanson JH, Toro-Fguero LO, et al.: Prospective, randomized comparison of high frequency oscillatory ventilation and conventional mechanical ventilation in pediatric respiratory failure. Crit Care Med 1994, 22:1530-1539.
107. Fort P, Farmer C, Westerman J, et al.: High-frequency oscillatory ventilation for adult respiratory distress syndrome: a pilot study. Crit Care Med 1997, 25:937-947.
108. Mehta S, Lapinsky SE, Hallet DC, et al.: A prospective trial of high frequency oscillatory ventilation in adults with acute respiratory distress syndrome. Crit Care Med 2001, 29:1360-1369. A first randomized controlled trial compared the safety and efficacy of high frequency oscillatory ventilation to conventional ventilation in ARDS.
109. Hirschl RB, Conrad S, Kaiser R, et al.: Partial liquid ventilation in adult patients with ARDS: a multicenter phase I-II trial. Ann Surg 1998, 228:692-700.
110. Stanley E, Lieschke GJ, Grail D, et al.: Granulocyte-macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994, 103:563-569.
111. Flohe S, Borgermann J, Dominguez FE, et al.: Influence of granulocyte-macrophage colony-stimulating factor (GM-CSF) on whole blood endotoxin responsiveness following trauma, cardiopulmonary bypass, and severe sepsis. Shock 1999, 12:17-24.
112. Presneill JJ, Harris T, Stewart AG, et al.: A randomized phase II trial of granulocyte-macrophage colony stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002, 166:138-143.